BioCentury

7:00 AM GMT, Jun 4, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

ProteoMediX: Prostate's PI3K biomarkers

ProteoMedix AG is developing a multiplexed ELISA-based blood test that aims to confirm an initial PSA positive result and reduce unneeded biopsies by monitoring a quartet of biomarkers associated with alterations in PI3K signaling, a common underlying cause of prostate cancer. The company believes its ELISA could have an advantage over competing tests because it measures the activity of a tumor suppressor that has been directly linked to disease development.

While the effectiveness of PSA testing as a screening tool remains a topic of intense debate, there is widespread agreement that new diagnostics are

Read the full 930 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.